Incidence, risk factors, and management of cardiovascular complications associated with acalabrutinib in patients with hematologic malignancy: A retrospective single-center cohort study
Latest Information Update: 12 Jan 2021
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Haematological malignancies
- Focus Adverse reactions
- 12 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology